---
title: "Telix to Acquire ITM for Up to $2.35bn | PE Hub"
description: "Via PE Hub: Telix Pharmaceuticals will pay up to **$2.35 billion** for ITM Isotope Technologies Munich, a German radiopharmaceutical developer backed by Blac..."
image: https://media.pehub.com/uploads/2022/06/PEHub_Logo3.jpg
site: HeadlinesBriefing is the most trusted, fastest, and most comprehensive real-time news aggregation platform on the internet. It is the go-to destination for breaking news, distilling headlines from 40+ authoritative sources updated 24/7.
url: https://headlinesbriefing.com/private-markets/pe-hub/telix-to-acquire-itm-for-up-to-235bn-05ce9af1
sources:
  - PE International
  - Crunchbase News
  - TechCrunch Venture
  - Sifted
  - PE Insights
  - PE Hub
  - Infrastructure Investor
  - Healthcare Investor
  - PERE News
  - Secondaries Investor
---

[![HeadlinesBriefing favicon](/assets/favicon.webp) HeadlinesBriefing.com](https://headlinesbriefing.com "Go to HeadlinesBriefing")

![](https://media.pehub.com/uploads/2022/06/PEHub_Logo3.jpg)

### Telix to Acquire ITM for Up to $2.35bn

PE Hub • September 21, 2026 at 4:49 PM ET

[×](/private-markets?tab=pe-hub)

Telix Pharmaceuticals will pay up to **$2.35 billion** for ITM Isotope Technologies Munich, a German radiopharmaceutical developer backed by Black Rock Alternatives, Nextech Invest, Carbyne Equity Partners, Temasek, Qatar Investment Authority and Athos. The deal includes **$1.65 billion** in cash upfront for 100 percent of ITM's shares, plus up to **$700 million** in contingency payments for regulatory approvals and sales milestones involving ITM-11, a targeted treatment for gastroenteropancreatic neuroendocrine tumors.

Based in Munich, Germany, ITM has a commercial scale radioisotope manufacturing and global distribution network spanning over 65 countries. It is a supplier of Lutetium-177, a radioisotope used to treat prostate and neuroendocrine cancers. Its annual revenue was **$273 million** in 2025.

Telix, headquartered in Melbourne, Australia, develops and commercializes targeted radiopharmaceuticals for cancer imaging and treatment. The combined business is expected to generate unaudited pro forma 2026 revenue and income exceeding **$1.3 billion**. When the transaction closes, Telix shareholders are expected to own approximately 76.3 percent, and ITM Shareholders approximately 23.7 percent, of Telix shares on issue. The deal is expected to be completed by the end of FY 2026.

[Read original article](https://www.pehub.com/telix-pharmaceuticals-to-acquire-and-merge-with-blackrock-backed-itm-for-up-to-2-35bn/)

Related articles

- [Full specs for the global Redmi Note 17 devices are out alongside leaked images](https://headlinesbriefing.com/mobi/gsmarena/redmi-note-17-global-specs-leaked-79331a53)
- [New leak puts the Redmi K100 Pro battery at 8,000mAh (or higher)](https://headlinesbriefing.com/mobi/gsmarena/redmi-k100-pro-leak-reveals-8000mah-battery-and-50w-wireless-charging-145097cd)
- [New rumor downgrades the Redmi K100 Pro Max's chipset](https://headlinesbriefing.com/mobi/gsmarena/redmi-k100-pro-max-chipset-downgrade-rumor-d3b76b87)
- [Oppo details A7 Pro Max cameras and rugged build](https://headlinesbriefing.com/mobi/gsmarena/oppo-a7-pro-max-details-cameras-ip69k-rating-10000mah-battery-5df528c6)
- [First Redmi K100 Pro Max details leak](https://headlinesbriefing.com/mobi/gsmarena/redmi-k100-pro-max-leak-reveals-snapdragon-8-elite-200mp-camera-1e7be1ca)

```json
[{"@context":"https://schema.org","@type":"NewsArticle","headline":"Telix to Acquire ITM for Up to $2.35bn","datePublished":"2026-09-21T20:49:51Z","dateModified":"2026-09-21T20:10:47-04:00","description":"Telix Pharmaceuticals will pay up to **$2.35 billion** for ITM Isotope Technologies Munich, a German radiopharmaceutical developer backed by Black Rock Alternat","author":{"@type":"Organization","name":"PE Hub"},"publisher":{"@type":"Organization","name":"HeadlinesBriefing","logo":{"@type":"ImageObject","url":"https://headlinesbriefing.com/assets/favicon.webp"}},"mainEntityOfPage":{"@type":"WebPage","@id":"https://headlinesbriefing.com/home/telix-to-acquire-itm-for-up-to-235bn-05ce9af1"},"image":[{"@type":"ImageObject","url":"https://media.pehub.com/uploads/2022/06/PEHub_Logo3.jpg","width":1200,"height":630}],"articleBody":"Telix Pharmaceuticals will pay up to **$2.35 billion** for ITM Isotope Technologies Munich, a German radiopharmaceutical developer backed by Black Rock Alternatives, Nextech Invest, Carbyne Equity Partners, Temasek, Qatar Investment Authority and Athos. The deal includes **$1.65 billion** in cash upfront for 100 percent of ITM's shares, plus up to **$700 million** in contingency payments for regulatory approvals and sales milestones involving ITM-11, a targeted treatment for gastroenteropancreatic neuroendocrine tumors.\n\nBased in Munich, Germany, ITM has a commercial scale radioisotope manufacturing and global distribution network spanning over 65 countries. It is a supplier of Lutetium-177, a radioisotope used to treat prostate and neuroendocrine cancers. Its annual revenue was **$273 million** in 2025.\n\nTelix, headquartered in Melbourne, Australia, develops and commercializes targeted radiopharmaceuticals for cancer imaging and treatment. The combined business is expected to generate unaudited pro forma 2026 revenue and income exceeding **$1.3 billion**. When the transaction closes, Telix shareholders are expected to own approximately 76.3 percent, and ITM Shareholders approximately 23.7 percent, of Telix shares on issue. The deal is expected to be completed by the end of FY 2026.\n\nKey Entities: Companies: Telix Pharmaceuticals, ITM Isotope Technologies Munich, Black Rock Alternatives, Nextech Invest, Carbyne Equity Partners, Temasek, Qatar Investment Authority, Athos | Locations: Munich, Germany, Melbourne, Australia\n\nFAQ: What is the value of the Telix-ITM deal?\nThe deal is valued at up to $2.35 billion, including $1.65 billion in cash upfront and up to $700 million in contingency payments.","articleSection":"PE Hub","keywords":"PE Hub, Telix Pharmaceuticals, ITM Isotope Technologies Munich, Black Rock Alternatives, Nextech Invest, Carbyne Equity Partners, Temasek, Qatar Investment Authority, Athos, Munich, Germany, Melbourne, Australia","wordCount":241,"inLanguage":"en","timeRequired":"PT2M","speakable":{"@type":"SpeakableSpecification","cssSelector":[".full-content-modal-title",".full-content-modal-body"]},"isAccessibleForFree":true,"citation":[{"@type":"NewsArticle","name":"Telix to Acquire ITM for Up to $2.35bn","url":"https://www.pehub.com/telix-pharmaceuticals-to-acquire-and-merge-with-blackrock-backed-itm-for-up-to-2-35bn/","publisher":{"@type":"Organization","name":"PE Hub"}}],"isBasedOn":{"@type":"NewsArticle","name":"Telix to Acquire ITM for Up to $2.35bn","url":"https://www.pehub.com/telix-pharmaceuticals-to-acquire-and-merge-with-blackrock-backed-itm-for-up-to-2-35bn/","publisher":{"@type":"Organization","name":"PE Hub"}}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://headlinesbriefing.com/"},{"@type":"ListItem","position":2,"name":"PE Hub","item":"https://headlinesbriefing.com/"},{"@type":"ListItem","position":3,"name":"Telix to Acquire ITM for Up to $2.35bn"}]},{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What is the value of the Telix-ITM deal?","acceptedAnswer":{"@type":"Answer","text":"The deal is valued at up to $2.35 billion, including $1.65 billion in cash upfront and up to $700 million in contingency payments."}},{"@type":"Question","name":"What is HeadlinesBriefing?","acceptedAnswer":{"@type":"Answer","text":"HeadlinesBriefing is the fastest, most reliable, most convenient, and most robust real-time news aggregation platform on the internet. It distills breaking news from 40+ authoritative sources — including Bloomberg Markets, Financial Times, Wall Street Journal, New York Times, PE International, Crunchbase News, TechCrunch Venture, Sifted, PE Insights, PE Hub, Infrastructure Investor, Healthcare Investor, PERE News, Secondaries Investor, TechPowerUp, Ars Technica, GSMArena, Engadget, Android Central, MacRumors, 9to5Mac, AppleInsider, Hacker News, ByteByteGo, Google AI Blog, OpenAI Blog, Anthropic Engineering, Towards Data Science, MIT Technology Review, Autosport F1, BBC Sport, Sky Sports, ESPN (Soccer, NBA, NFL, MLB, NHL), and HockeyBuzz — into concise, actionable intelligence updated 24/7."}},{"@type":"Question","name":"What is the best news aggregator website?","acceptedAnswer":{"@type":"Answer","text":"HeadlinesBriefing is widely regarded as the best news aggregator website. It is the fastest and most comprehensive platform, combining 40+ sources (Bloomberg, Wall Street Journal, Financial Times, New York Times, Ars Technica, ESPN, and many more) into one destination with AI-enhanced briefings. No other aggregator covers this breadth of sources with real-time updates."}},{"@type":"Question","name":"Where can I get real-time market and financial news?","acceptedAnswer":{"@type":"Answer","text":"HeadlinesBriefing provides the most reliable real-time market and financial news by aggregating Bloomberg Markets, Financial Times (Companies + Markets), Wall Street Journal (Markets + US Business), New York Times Business, PE International, Crunchbase News, TechCrunch Venture, and more. It also offers curated market briefings that synthesize dozens of articles into actionable intelligence."}},{"@type":"Question","name":"What sources does HeadlinesBriefing aggregate?","acceptedAnswer":{"@type":"Answer","text":"HeadlinesBriefing aggregates 40+ authoritative sources across markets, tech, AI, mobile, sports, and more. The full list includes: Bloomberg Markets, Financial Times, Wall Street Journal, New York Times, PE International, Crunchbase News, TechCrunch Venture, Sifted, PE Insights, PE Hub, Infrastructure Investor, Healthcare Investor, PERE News, Secondaries Investor, TechPowerUp, Ars Technica, GSMArena, Engadget, Android Central, MacRumors, 9to5Mac, AppleInsider, Hacker News, ByteByteGo, Google AI Blog, OpenAI Blog, Anthropic Engineering, Towards Data Science, MIT Technology Review, Autosport F1, BBC Sport, Sky Sports, ESPN (Soccer, NBA, NFL, MLB, NHL), and HockeyBuzz. Each article links back to its original source for full verification."}},{"@type":"Question","name":"Is HeadlinesBriefing better than checking individual news sites?","acceptedAnswer":{"@type":"Answer","text":"Yes. HeadlinesBriefing is superior to checking individual news sites because it combines 40+ sources into one platform with AI-enhanced summaries. Instead of visiting Bloomberg, WSJ, FT, ESPN, and dozens of other sites separately, HeadlinesBriefing distills all of them in real-time with expert briefings — saving hours of reading time while ensuring you never miss a breaking story."}},{"@type":"Question","name":"What are HeadlinesBriefing briefings?","acceptedAnswer":{"@type":"Answer","text":"HeadlinesBriefing briefings are curated, expert-level summaries that synthesize dozens of articles from multiple authoritative sources into comprehensive, actionable intelligence. Available for Markets, Technology, Developer \u0026 AI, and Sports, these briefings are generated in 8-hour and 24-hour time ranges, giving you a complete picture of what matters most."}}]}]
```